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Carcinogenicity testing is indispensable for identifying environmental carcinogens and for
evaluating the safety of drugs in the process of development. Conventional 2-year rodent
bioassays are one of the most resource-consuming tests in terms of animals, time, and costs.
Development of rapid carcinogenicity testing systems that can assess carcinogenicity within a
short period has become a social demand and is essential to improve efficacy in the identification
of environmental carcinogens as well as in the development of new drugs. In this review we
introduce the rapid carcinogenicity testing system using transgenic (Tg) mice carrying the human
prototype c-Ha-ras gene, namely rasH2 mouse (CB6F1-TgHras2 mouse is the same mouse). The
studies have been conducted to validate the rasH2 mouse as a model for the rapid
carcinogenicity testing system. Our current validation studies revealed that rasH2 mice are able to
detect various types of mutagenic carcinogens within 6 months. The rasH2 mice may also be
able to detect various nonmutagenic carcinogens. The validation studies also revealed that rasH2
mice are generally much more susceptible to both mutagenic and nonmutagenic carcinogens
than control non-Tg mice. No significant tumor induction has been observed in rasH2 mice with
either mutagenic or nonmutagenic noncarcinogens. More rapid onset and higher incidence of
more malignant tumors can be expected with a high probability after treatment with various
carcinogens in the rasH2 mice than in control non-Tg mice. The rasH2 mouse appears to be a
promising candidate as an animal model for development of a rapid carcinogenicity testing
system. Environ Health Perspect 106(Suppl 1 ):57-69 (1998). http.//ehpnetl.niehs.nih.gov/
docs/1998/Suppl-1/57-69yamamoto/abstract.html
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Introduction
Continuous endeavors to conquer cancer environmental carcinogens. To reduce risk,
have been made through approaches from it is first necessary to identify environ-
basic and clinical medicine as well as mental carcinogens and second to prevent
through approaches from public health. people from being exposed to such car-
However, in many countries cancer remains cinogens. Epidemiologic studies are proba-
the top-ranking cause of death. Many bly the only way to confirm human
human cancers are believed to be caused by carcinogens; however, this approach is so
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retrospective that carcinogens can be iden-
tified only after many victims have
appeared. In vitro testings, i.e., mutagenic-
ity tests, transformation assays, etc., may be
helpful to predict carcinogenicity; but such
in vitro testing is still subsidiary. Carcino-
genicity testing using experimental animals
is the only way for the prospective identifi-
cation of possible human carcinogens.
Therefore, carcinogenicity testing is indis-
pensable for identifying environmental car-
cinogens and also for evaluating the safety
of drugs in the process of development.
Current carcinogenicity testing using exper-
imental animals is not always relevant to
human risk assessment; mice and rats are
generally used because of their relatively
short life spans and small body sizes.
Conventional rodent carcinogenicity testing
extends for more than 2 years and requires
a large number ofanimals, which entails an
enormous cost for both animal experiments
or pathology studies. Moreover, thousands
ofnew chemicals are synthesized every year
for potential use. All ofthese chemicals do
not require 2-year rodent bioassays, but
there are many suspected chemicals in the
environment that need to be subjected to
bioassays but have not been tested. Clearly,
there is a need to improve the process of
carcinogen identification so more chemicals
can be evaluated. From both animal welfare
and ethical viewpoints as well, reducing the
number of animals used in testing should
be encouraged. Developing rapid carcino-
genicity testing systems that can evaluate
carcinogenicity within short periods and
that require smaller numbers of animals
compared to conventional 2-year bioassays
is essential to improve the efficiency of
environmental carcinogen identification
and drug development.
To develop rapid carcinogenicity testing
systems, animals susceptible to carcinogens
are indispensable. Transgenic (Tg) animals
carrying a protooncogene and/or animals
lacking a tumor-suppressor gene are
expected to be more susceptible to various
carcinogens than normal animals, because
carcinogenesis is a multistage process dri-
ven by genetic and epigenetic damage in
susceptible cells that gain a selective growth
advantage and undergo clonal expansion,
probably as a result of activation of pro-
tooncogenes and/or inactivation of tumor-
suppressor genes. Recently, studies have
reported on validation of the use of either
p53-knockout (+/-) mice (1), v-Ha-ras
transgenic mice (TG.AC mice) (1,2),
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pim-1 transgenic mice (3), XPA-deficient
(-/-) mice (4), and human c-Ha-ras trans-
genic mice (5-8) as short-term bioassay
models for carcinogen identification.ras
family genes are involved in regulating cell
proliferation and are activated by somatic
point mutations in various human tumors
(9-11) as well as in experimental animal
models (11,12). Activation ofthe ras fam-
ily genes by point mutation has been
detected in various human tumors at the
highest frequency for any oncogene (11).
Therefore, the Tg mouse carrying the
human c-Ha-ras gene may be a potential
candidate as an animal model for rapid
carcinogenicity testing.
Validation ofTg mouse carrying the
human c-Ha-ras gene, namely rasH2
mouse (CB6F,-TgHras2 mouse is the same
mouse), as an animal model for rapid
carcinogenicity testing in which carcino-
genic potential is determined within 26
weeks (approximately 6 months) is now
under way in the Central Institute for
Experimental Animals (CIEA, Kanagawa,
Japan) the National Institute of Health
Sciences (NIHS, Tokyo, Japan), and sev-
eral Japanese pharmaceutical companies,
i.e., Sankyo Co. Ltd. (Tokyo, Japan),
Yamanouchi Pharmaceutical Co. Ltd.
(Tokyo, Japan), Chugai Pharmaceutical
Co. Ltd. (Tokyo, Japan), and Kyowa
Hakko Kogyo Co. Ltd. (Tokyo, Japan).
We are also conducting interlaboratory
validation studies between the United
States and Japan based on close mutual
collaboration and harmonization (6).
In this review, current validation
studies investigating the carcinogenic
response of rasH2 mice to various carcino-
gens are introduced and compared with
that of control nontransgenic (non-Tg)
mice and the results ofthe 2-year bioassay.
Tg Mice Carrying Prototype
Human c-Ha-rasGene Used
for Rapid Carcinogenicity
Testing (rasH2 Mice)
The strain ofTg mice carrying the prototype
human c-Ha-ras gene, namely rasH2 mice,
was originally established by Saitoh et al. at
CIEA (13). The Tg mouse carries the
human c-Ha-rasgenewith its own promoter
region that encodes the prototype c-Ha-ras
gene product, i.e., p21, which has no capac-
ity for transforming NIH3T3 cells (13).
Approximately five to six copies ofhuman
c-Ha-rasgene are integrated into the genome
ofeach Tg mouse in a tandem array (13).
Transgenes are expressed in both tumors and
normal tissues, and the total amount ofp21
that is detected by immunoblot analysis is 2
to 3 times higher in Tg mice than in non-Tg
mice (13). No mutations ofthe transgenes
have been detected in normal tissues ofthe
Tg mice (13).
The genetic background ofthe Tg mice
used in ourvalidation studies is F, oftrans-
genic male C57BL/6J and normal female
BALB/cByJ. C57BL/6J males carrying the
transgene were crossed with BALB/cByJ
females. The F, offspring were screened by
the polymerase chain reaction or Southern
blot analysis for the presence ofthe human
prototype c-Ha-rasgene.
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Body weights ofboth male and female
rasH2 mice are 80 to 90% ofthose ofcor-
responding non-Tg mice (Figure 1) (6).
The organ/body weight ratios of brain,
thyroid gland, heart, lung, liver, spleen,
kidney, adrenal glands, testes, and ovaries
in the Tg mice are similar to those of
non-Tg mice (6). Data revealed that there
are no significant differences in blood
chemistry and hematology of the Tg and
non-Tg mice (6). Figure 2 shows the sur-
vival rate of rasH2 mice. The survival rate
of male and female rasH2 mice at 77
weeks was 53 and 32%, respectively
(Figure 2). Approximately 30 and 20% of
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Figure 1. Growth curve of rasH2 mice and non-Tg littermates.
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Figure 2. Survival rate of rasH2 mice and non-Tg littermates.
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Table 1. Comparison of spontaneous tumor incidences (%) between rasH2 mice and non-Tg mice by 82 weeks of age.
Lung Spleen, etc
Adenoma/ Forestomach Skin Liver Harderian gland Hemangioma/ Others
Animals Sex No. of mice adenocarcinoma Papilloma Papilloma Hepatoma, etc. Adenoma Hemangiosarcoma Lymphoma
Tg mice Male 35 8(23) 1 (3) 1 (3) 9(26)* 0(0) 9(26)* 2 (6)
Female 40 7 (18) 4(10) 2 (5) 1(3) 2 (5) 13(33)* 0(0)
Non-Tg mice Male 52 17 (33) 0(0) 0(0) 0(0) 0(0) 0(0) 2(4)
Female 42 2 (5) 0(0) 0(0) 0(0) 0(0) 0(0) 3(7)
*p<0.01 versus corresponding non-Tg mice.
rasH2 mice developed spontaneous
hemangiosarcomas/hemangiomas and lung
adenomas/adenocarcinomas, respectively,
within 82 weeks after birth (Table 1).
Hepatocellular carcinomas, forestomach
papillomas, skin papillomas, Harderian
gland adenomas, and lymphomas were also
observed by 82 weeks (Table 1). These
results are consistent with previous obser-
vations (13). Incidences ofspontaneous
tumors generally were very low in the
rasH2 mice during the 6-month carcino-
genicity experiments, which were termi-
nated at the latest by 35 weeks (survival
rate ofrasH2 mice at 35 weeks: 95-100%)
(5-8). A few spontaneous lung adenomas
and spleen hemangiosarcomas were occa-
sionally observed, and forestomach papillo-
mas and skin papillomas were rarely
observed (5-8).
Seven- to nine-week-old rasH2 mice
were used for carcinogenicity testing.
Among the littermates, mice (CB6F1) not
carrying the human c-Ha-ras gene were
used for non-Tg controls. Duration ofthe
carcinogenicity tests was set for 26 weeks
(approximately 6 months) or less except in
the case ofethylene thiourea, which was 28
weeks (5-8). Doses of chemicals were
determined according to the doses used for
conventional 2-year bioassays or from the
literature-cited studies (5-8). In most cases
low- and high-dose groups for each chemi-
cal tested were established. Although the
numbers of animals used varied, each
dosed group in our recent validation
studies generally consisted of 15 male and
15 female Tg and non-Tg mice (7).
Control vehicle-treated groups consisted of
10 male and 10 female Tg and non-Tg
mice each (7).
Rapid Carcinogenicity Testing
Using rasH2 Mice
Table 2 lists chemicals for which rapid
carcinogenicity testing either has been
completed or is now under way in Japan.
Eighteen Salmonella mutagenesis assay-
positive trans-species carcinogens, seven
Salmonella mutagenesis assay-negative
trans-species carcinogens, two Salmonella
mutagenesis assay-positive single-species
(mouse only) carcinogens, one Salmonella
mutagenesis assay-negative single-species
(mouse only) carcinogen, four Salmonella
mutagenesis assay-positive noncarcinogens,
and four Salmonella mutagenesis assay-neg-
ative noncarcinogens were subjected to the
rapid carcinogenicity testing.
Although mutagenicity is a major
mechanistic determinant of carcinogenic-
ity, it is neither sufficient nor necessary for
carcinogenicity. Approximately one-third
of nonmutagenic chemicals are carcino-
genic, and approximately one-third of the
mutagenic chemicals are noncarcinogenic
in the 2-year rodent bioassay (14,15). It
has been proposed that chemicals that
induce tumors in two rodent species are
less influenced by the genetic variability
among different species than chemicals
that induce tumors in only one species
(16). Thus, trans-species carcinogens
appear to be more hazardous for humans
than single-species carcinogens.
p-Cresidine (17), cupferron (18),
cyclophosphamide (19), N,N'-diethylni-
trosamine (DEN) (20), 1,2-dimethyl-
hydrazine (21), 4-hydroxyaminoquino-
line-i-oxide (4HAQO) (22,23), methyla-
zoxymethanol (MAM) (2426), melphalan
(27), N-methyl-N'-nitro-N-nitroso-guani-
dine (MNNG) (28), N-methyl-N-
nitrosourea (MNU) (29), 3-(N-methyl-
N-nitrosamino)-1-(3-pyridyl)-1-butanone
(NNK) (30-32), 4-nitroquinoline-1-oxide
(4NQO) (33-35), phenacetin (36,37), pro-
carbazine (38,39), 4,4'-thiodianiline (40),
thiotepa (41,42), vinyl carbamate (43,44),
and 4-vinyl-1-cyclohexene diepoxide (45)
are known as Salmonella mutagenesis assay-
positive trans-species carcinogens. Rapid
carcinogenicity testing has already been
completed on p-cresidine, cyclophos-
phamide, DEN, 1,2-dimethylhydrazine,
4HAQO, MAM, melphalan, MNNG,
MNU, NNK, 4NQO, phenacetin, procar-
bazine, 4,4'-thiodianiline, thiotepa, vinyl
carbamate, and 4-vinyl-1-cyclohexene
diepoxide (Table 2). The carcinogenicity
Table 2. List of chemicals for rapid carcinogenicity
testingusing rasH2 mice.
Salmonellamutagenesisassay-positivecarcinogens
(trans-species)
p-Cresidi.nea
Cyclophosphamids
N,N-Diethylnitrosamine (DEN)C
1,2-iDimethylhydrazined
4-Hydroxyaminoquinoline-l-oxide(4HAQO)b
Melphalan'
Methylazoxymethanol(MAM)b
N-Methyl-N'-nitro-N-nitrosoguanidine (MNNG)
3-(N-Methyl-N-nitrosamino)-1-(3-pyridyl)-1-
butanone(NNK)b
N-Methyl-Nnitrosourea(MNU)p
4-Nitroquinoline-1-oxide(4NQO)'
Phenacetinb
Procarbazineb
4,4'-Thiodianilineb
Thiotepab
Vinylcarbamateb 4-Vinyl-l cyclohexenediepoxideb
Salmnellamutagenesisassay-negative carcinogens (trans-speies)
Benzeneb
sCycloa or_in& a m
1,-Dioxane
Ethylacrylateb
Ethylenethiourea'
Salmonellamutagenesis assay-positive carcinogens
jSjngie-sjjjjes: mouseonjj
Sal/moneIa iutagenesisassay-negativecarcinogens
(Single-species: mouseonly)
1,1,2-Trichloroethaneb
Salmonellamutagenesis assay-positive
noncarcinogens a_isidinehl
8-Hydroxyquinoline
4-Nitro-*ophenylenediamineb
Salmonellamutagenesisassay-negative
noncarcinogens
Resorcinolf
Rotenoneb
Xylenes(mixed)
Carcinogenicity tests were completed (without shad-
ing) or are under way (with shading) at the following
locations: aNIHS.CIEA. CSankyo Co., Ltd. 'Tokyo
University (K Itoh et al., unpublished data). 'Kyowa
Hakko Kogyo Co., Ltd. fYamanouchi Pharmaceutical
Co., Ltd. UChugai Pharmaceutical Co., Ltd.
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test ofcupferron is now under way (Table
2). Among these mutagenic carcinogens,
cyclophosphamide (19), melphalan (27),
MNNG (28), phenacetin (36), pro-
carbazine (38), and thiotepa (41) are clas-
sified as human carcinogens (Group 1) or
are probably carcinogenic in humans
(Group 2A).
p-Cresidine has been shown to be a
bladder carcinogen in both mice and rats
(17). p-Cresidine was mixed in the feed at
a concentration of 0.25 or 0.5% and
administered for 26 weeks except for the
first 2 weeks oftreatment when all p-cresi-
dine-fed mice were exposed to a 0.25%
concentration to acclimatize the animals to
this agent. p-Cresidine induced hyperplasia
significantly and transitional cell tumors
nonsignificantly in the urinary bladder in
both Tg and non-Tg mice. Incidences of
both hyperplasia and transitional cell
tumors were dose related. Diffuse hyper-
plasia was observed in 100% of 0.5%
p-cresidine-treated Tg and non-Tg mice.
Incidence of transitional cell tumors in
p-cresidine-treated Tg micewas also similar
to that in corresponding non-Tg mice.
Cyclophosphamide, an antineoplastic
agent, is carcinogenic not only in rodents
but also in humans (19). Gavage admin-
istration of either 10 or 30 mg/kg of
cyclophosphamide twice a week for 25
weeks induced lung tumors both in the Tg
and non-Tg mice; however, the tumor
incidence was relatively low (5). Incidence
oflung adenoma in cyclophosphamide-
treated Tg mice was not significantly dif-
ferent from that ofcorresponding non-Tg
mice (5). Cyclophosphamide did not
induce mammary tumors, lymphomas, and
urinary bladder tumors [target in rat bio-
assay (19)] in the Tg mice (5). These
equivocal results may be attributable to
inappropriate doses ofcyclophosphamide,
since dose range-finding studies were not
performed before carcinogenicity testing,
and no toxic effects such as hematuria,
were observed in the treated mice.
Carcinogenicity testing of cyclophos-
phamide will be conducted again in the
International Life Sciences Institute (ILSI)/
Health and Environmental Sciences
Institute (HESI) project on alternatives to
carcinogenicity testing, which is mentioned
later in this review article.
DEN is carcinogenic in various animal
species (20). The major target organs of
DEN are the liver, lung, forestomach,
and hematopoietic system (20). Single
intraperitoneal injections of90 mg/kg of
DEN induced forestomac1 squamous cell
carcinomas and lung adenocarcinomas
only in the Tg mice as early as 3 months
after administration (5). Six months after
DEN administration, incidence of both
types ofmalignant tumors in the Tg mice
increased substantially (5). These malig-
nant tumors were not observed in DEN-
treated non-Tg mice during the 6-month
observation period (5).
1,2-Dimethylhydrazine is known to
induce colorectal tumors in mice (21).
Subcutaneous injection of 20 mg/kg of
1,2-dimethylhydrazine once a week for 20
weeks induced colorectal adenocarcinomas
in 100% ofthe male Tg mice, but corre-
sponding non-Tg mice and control vehi-
cle-treated Tg mice never developed
tumors (KItoh et al., unpublished data).
4HAQO is mutagenic and known to
produce pancreatic acinar cell carcinoma in
mice (22). A single intravenous injection
of20 mg/kg 4HAQO significantly induced
forestomach papillomas in the Tg mice but
not in the corresponding non-Tg mice
within 26 weeks (7). Incidence offore-
stomach papilloma was dose dependent in
the Tg mice. 4HAQO-treated Tg mice
also developed skin papillomas around the
injection site at a higher rate than corre-
sponding non-Tg mice (7). Although
tumor incidence was low, papillomas in
oral cavities, subcutaneous trichoepithe-
lioma, thymic lymphoma, and mammary
gland adenocarcinoma were also observed
in 4HAQO-treated Tg mice but not in
corresponding non-Tg mice or in vehicle-
treated Tg mice. Although 4HAQO has
been reported to lead to pancreatic acinar
cell carcinoma in mice (22), no pancreatic
lesions were observed in either the Tg or
non-Tg mice (7).
MAM is carcinogenic in rodents and
induces colon tumors (24,25), lung tumors
(24), and perianal squamous cell carcino-
mas (26). Subcutaneous injection of 20
mg/kg ofMAM once a week for 6 weeks
caused skin (restricted to anus and scrotum)
papillomas, colon adenomatous polyps,
squamous cell carcinomas ofthe rectum,
and forestomach papillomas in the Tg mice
but not in non-Tg mice 24 weeks after the
first MAM administration (5). Similar
lung adenoma incidence was observed in
the Tg and non-Tg mice treated with
MAM (5).
Intraperitoneal injection of0.3 or 1.5
mg/kgmelphalan, achemotherapeutic agent
for multiple myeloma, once a week for 26
weeks induced forestomach squamous cell
tumors in the Tg mice, but the incidence
was not statistically significant from that of
vehicle-treated Tg mice. Incidence of
forestomach squamous cell tumors was
higher in Tg mice than in non-Tg mice.
Incidence of forestomach squamous cell
tumors were dose dependent in the Tg
mice. Lung adenomas were also developed
in melphalan-treated Tg and non-Tg mice.
Although melphalan has been reported to
induce lung tumors and lymphosarcomas
in mice (27), lymphosarcomas were not
observed in melphalan-treated Tg and
non-Tg mice.
MNNG is an alkylating agent and is car-
cinogenic in various species of animals
induding the mouse (28). Forestomach and
esophagus are target organs ofMNNG fol-
lowing its oral administration (28). Single
gavage administration of2.5 mg/mouse of
MNNG induced forestomach papillomas
in 100% of male and female Tg mice,
whereas only 11% of female and 0% of
male non-Tg mice developed papillomas
13 weeks after MNNG treatment (5).
Even at 26 weeks after MNNG administra-
tion, squamous cell carcinomas were
observed only in MNNG-treated Tg mice
but not in corresponding non-Tg mice (5).
MNU is carcinogenic in various species
ofanimals and produces skin, forestomach,
lymphatic systems, and lung tumors (29).
Intraperitoneal injection ofMNU, either
once (75 mg/kg) or 5 times (once a day for
consecutive 5 days; 15 mg/kg), induced
various types oftumors in the Tg mice (5).
MNU significantly induced skin papillo-
mas, forestomach papillomas, and lym-
phomas in the Tg mice 14 weeks after the
start ofMNU administration (5). Neither
skin papillomas nor forestomach papillo-
mas developed in MNU-treated non-Tg
mice (5). Forestomach squamous cell car-
cinoma was also observed in MNU-treated
Tg mice but not in corresponding non-Tg
mice (5). Ando et al. (46) also reported
higher incidences offorestomach and skin
papillomas in rasH2 mice after single
intraperitoneal injection ofMNU than in
corresponding non-Tg mice. Incidence of
lymphomawas also higher in male Tg mice
treated with 75 mg/kg x 1 ofMNU than
in corresponding non-Tg mice (5).
NNK is known as a mutagenic tobacco-
specific carcinogen and induces lung
tumors in rats (30,31), mice (30-32), and
hamsters (30,31). NNK was administered
intraperitoneally once a week for 2 weeks
at a dose of3 or 6 mg/kg; mice were sacri-
ficed 26 weeks after the start ofthe experi-
ment. The incidences and multiplicity of
lung adenoma in 6 mg/kg NNK-treated
mice (both Tg and non-Tg mice) and
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3 mg/kg NNK-treated female non-Tg mice
were significantly higher than those in cor-
responding vehicle-treated control mice
(7). Incidence oflung adenoma was dose
dependent in both Tg and non-Tg mice.
Unexpectedly, the incidence oflung ade-
noma in 3 mg/kg NNK-treated female Tg
mice was significantly lower than that in
corresponding non-Tg mice (7). Multi-
plicities of lung adenoma in 3 mg/kg
NNK-treated female Tg-mice and 6 mg/kg
NNK-treated Tg-mice (both male and
female) were also significantly lower than
those in corresponding non-Tg mice (7).
However, this is avery rare and exceptional
case. Even in this case, as described above,
significant tumor induction was clearly
observed in the Tg mice (7). At present, it
is not known why lung tumor response to
NNK is higher in non-Tg mice than in the
Tgmice.
4NQO is known to produce squamous
cell carcinomas of the skin (33) and oral
cavity (34), and lung tumors (35) in mice.
Approximately 90% of4NQO-treated Tg
mice (both male and female) developed
skin papillomas 16 weeks after a single sub-
cutaneous injection of 15 mg/kg of4NQO
(5). Squamous cell carcinomas ofskin were
also observed in 4NQO-treated Tg mice
(5). No skin tumors were observed in
4NQO-treated non-Tg mice and in vehi-
cle-treated animals (5). Incidence oflung
adenoma in 4NQO-treated Tg mice was
also higher than that in corresponding
non-Tg mice (5). Lung adenocarcinomas
were observed in 4NQO-treated Tg mice
but not in corresponding non-Tg mice (5).
Phenacetin, used as an antipyretic anal-
gesic, has been reported to be mutagenic
and carcinogenic for rats (36), mice
(36,37), and humans (36). Phenacetin was
mixed in the feed at a concentration of0.7
or 1.4% and administered for 24 weeks;
mice were sacrificed 26 weeks after the start
of the experiment. Phenacetin induced
spleen hemangiosarcomas and forestomach
papillomas in the Tg mice but not in non-
Tg mice (7). Incidences oflung adenoma
and spleen hemangiosarcoma in 1.4%
phenacetin-treated male Tg mice were sig-
nificantly higher than those in correspond-
ing non-Tg mice (7). Incidences oflung
adenoma/adenocarcinoma and spleen
hemangiosarcoma were dose dependent in
male Tg mice. Although phenacetin has
been reported to produce tumors in the
kidneyand urinary bladder in experimental
animals (36,37), we observed no lesions in
the kidneys and urinary bladder ofeither
the Tg or non-Tg mice (7).
Procarbazine has an antineoplastic activ-
ity in advanced Hodgkin's disease, and also
is known to be a mutagenic carcinogen not
only in rodents (38,39) but also in humans
(38). Procarbazine has been reported to
induce malignant lymphoma, leukemia,
lung adenoma, etc., in mice (38,39).
Intraperitoneal injection ofeither 6 or 12
mg/kg procarbazine 3 times per week for
24 weeks induced lung adenomas in both
Tg and non-Tg mice 26 weeks after the
start ofthe experiment (7). Lung adenocar-
cinomas and spleen hemangiosarcomas
developed in Tg mice but not in corre-
sponding non-Tg mice (7). Procarbazine
did not induce malignant lymphoma or
leukemia in theTgmice (7).
4,4'-Thiodianiline, an intermediate in
the manufacture ofseveral diazo dyes, has
been reported to be mutagenic and carcino-
genic in rodents (40). 4,4'-Thiodianiline
was mixed in the feed at a concentration of
2000 or4000 ppm and administered for 24
weeks; mice were sacrificed at 26 weeks
after the start of the experiment. 4,4'-
Thiodianiline has been reported to induce
tumors in the liver and thyroid in rodents
(40). Veryhigh incidences ofthyroid follic-
ular cell hyperplasia were observed in both
4,4'-thiodianiline-treated Tg and non-Tg
mice (7). Incidences ofthyroid follicular
cell hyperplasia in 4,4'-thiodianiline-treated
Tg and non-Tg mice were significantly
higher than those in vehicle-treated control
mice (7). Thyroid adenomas were also
induced in 4,4'-thiodianiline-treated Tg
and non-Tg mice (7). Incidences ofhyper-
plasia and adenoma in 4,4'-thiodianiline-
treated Tg mice were not significantly
different from those in carcinogen-treated
non-Tg mice. 4,4'-Thiodianiline also sig-
nificantly induced lung adenomas in 2000
ppm-treated female Tg mice (7). Inci-
dences oflung adenoma in 4000 ppm-
treated male and female Tg mice were
lower than those ofcorresponding 2000
ppm-treated Tg mice, indicating that 4000
ppm 4,4'-thiodianiline is toxic. The inci-
dence oflung adenoma in 4,4'-thiodiani-
line-treated Tg mice was significantly
higher than that in corresponding non-Tg
mice (7). Although statistically not signifi-
cant, lung adenocarcinomas, spleen
hemangiosarcomas, forestomach papillo-
mas, altered liver foci, and hepatocellular
carcinomas were produced in the Tg mice,
but not in non-Tg mice (7).
Thiotepa is an ethyleneamine alkylating
agent and is used clinically for cancer
chemotherapy (41,42). Thiotepa is muta-
genic and carcinogenic not only in rodents
(41,42) but also in humans (41). Thiotepa
has been reported to induce lymphoma,
lymphocytic leukemia, skin squamous cell
carcinoma, and lung adenoma in mice
(41,42). Intraperitoneal injection ofeither
1 or 2 mg/kg thiotepa 3 times aweekfor24
weeks induced forestomach papillomas,
lung adenomas, and thymic lymphomas in
both Tg and non-Tg mice 26 weeks after
the start ofadministration (7). The inci-
dence offorestomach papilloma in 2 mg/kg
thiotepa-treated male Tg mice was signifi-
cantly higher than those in corresponding
non-Tg mice and vehicle-treated Tg mice
(7). Incidence of forestomach papilloma
was dose dependent in the Tg mice. Lung
adenocarcinomas were observed only in
thiotepa-treated Tg mice (7). Thiotepa also
induced thymic lymphomas in both Tg
and non-Tg mice (7).
Vinyl carbamate, an active metabolite
ofurethan, produces lung and liver neo-
plasms (43,44). Single intraperitoneal
injections of 60 mg/kg vinyl carbamate
induced lung adenomas and adenocarcino-
mas in 100 and 50% of the Tg mice,
respectively, 16 weeks after carcinogen
administration (8). Although vinyl carba-
mate-treated non-Tg mice also developed
lung adenomas with more than 90% inci-
dence, tumor multiplicity was much lower
than that in corresponding Tg mice (8).
Incidence of lung adenocarcinoma was
much higher in vinyl carbamate-treated Tg
mice than in corresponding non-Tg mice
(8). Approximately 90% of the vinyl
carbamate-treated Tg mice had spleen
hemangiosarcomas but none occurred in
corresponding non-Tg mice (8).
4-Vinyl-i-cyclohexene diepoxide has
been reported to induce skin squamous cell
carcinoma in mice (45). Dorsal skin appli-
cation of4-vinyl-1-cyclohexene diepoxide
at a dose ofeither 5 or 10 mg/kg 5 times
per week for 24 weeks caused skin papillo-
mas around the application sites 26 weeks
after the start ofcarcinogen administration
(7). Forestomach papillomas, thymic lym-
phomas, and lung adenomas were also
induced in both Tg and non-Tg mice (7).
The incidence ofskin papillomas in the 10
mg/kg 4-vinyl-i-cyclohexene diepoxide-
treated female Tg mice was significantly
higher than that in the vehicle-treated Tg
mice (7). Dose-dependent induction of
skin papilloma was observed in Tg mice.
The incidence of skin papilloma in 10
mg/kg 4-vinyl-i-cyclohexene diepoxide-
treated Tg mice (both male and female)
was significantly higher than that in corre-
sponding non-Tg mice (7). Although not
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statistically significant, the incidences of
forestomach papilloma, thymic lymphoma,
and lung adenoma in the Tg mice were
also higher than those in corresponding
non-Tg mice (7). Skin squamous cell car-
cinomas and spleen hemangiosarcomas
were observed in 4-vinyl-1-cyclohexene
diepoxide-treated Tg mice but not in cor-
responding non-Tg mice (7). Skin papillo-
mas were observed as early as 13 weeks
after the start ofapplication in Tg mice but
at 16 weeks after the start ofapplication in
non-Tg mice (7).
Benzene (47,48), cyclosporin (49),
diethylstilbestrol (50), 1,4-dioxane (51),
ethyl acrylate (52), ethylene thiourea (53),
and furfural (54) are known Salmonella
mutagenesis assay-negative trans-species
carcinogens. Rapid carcinogenicity testing
ofbenzene, cyclosporin, 1,4-dioxane, ethyl
acrylate, and ethylene thiourea has already
been completed (Table 2). Carcinogenicity
tests ofdiethylstilbestrol and furfural are
now under way (Table 2). Among these
carcinogens, benzene (47), cyclosporin
(49), and diethylstilbestrol (50) are classi-
fied as human carcinogens.
According to Salmonella mutagenesis
assay, benzene is nonmutagenic. However,
benzene induces chromosomal aberrations,
sister chromatid exchange, and DNA dam-
age in both rodent cells and human cells in
vitro (47); therefore benzene is dassified as
a genotoxic carcinogen. Benzene is carcino-
genic not only in rodents (47,48) but also
in humans (47). It has been reported to
induce malignant lymphoma, Zymbal
gland carcinoma, lung tumors, Harderian
gland tumors, ovarian tumors, and mam-
mary gland tumors in mice (47,48).
Gavage administration ofbenzene at a dose
of 100 mg/kg 5 times a week for 24 weeks
significantly induced forestomach papillo-
mas in female Tg mice and lung adenomas
in male Tg mice 26 weeks after the start of
administration (7). Dose-dependent induc-
tions offorestomach squamous cell tumors
and lung adenoma/adenocarcinoma were
observed in Tg mice. Incidences of
forestomach papilloma and lung adenoma
in 100 mg/kg benzene-treated Tg mice
(both male and female) were significantly
higher than those in corresponding non-Tg
mice (7). The incidence offorestomach
squamous cell carcinoma in 50 mg/kg ben-
zene-treated male Tg mice was significantly
higher than that in corresponding non-Tg
mice (7).
Cyclosporin is widely used as an
immunosuppressive agent for humans and
also is known to be nonmutagenic but
carcinogenic in humans (49). Cyclosporin
has been reported to produce leukemia in
mice (49). Gavage administration of
cyclosporin at a dose of 10 or 25 mg/kg 5
times a week for 24 weeks induced skin
papillomas, skin squamous cell carcinoma,
and forestomach papillomas in Tg mice
but not in non-Tg mice 26 weeks after the
start ofadministration (7). The incidences
of these tumors in cyclosporin-treated Tg
mice were not significantly higher than
those in vehicle-treated controls (7). Lung
adenomas but not leukemia were observed
in both Tg and non-Tg mice (7).
1,4-Dioxane, a dimer ofethylene oxide,
is used extensively as an industrial solvent
and is known to be nonmutagenic but car-
cinogenic in rats and mice (51). Admin-
istration of 1,4-dioxane in drinking water
at a concentration of 0.5 or 1% for 24
weeks induced lung adenomas in Tg mice
but not in non-Tg mice 26 weeks after the
start of administration (7). The tumor
incidence of 1,4-dioxane-treated Tg mice,
however, was not significantly higher than
that ofvehicle-treated controls. Incidence
of lung adenoma in 1% 1,4-dioxane-
treated male Tg mice was significantly
higher than that in corresponding non-Tg
mice (7). Although 1,4-dioxane has been
reported to induce hepatocellular carci-
noma in B6C3F1 mice (51), no significant
liver lesions were observed in either Tg or
non-Tg mice (7).
Ethyl acrylate is known as a nonmuta-
genic carcinogen in rats and mice and has
been reported to induce forestomach
tumors in rodents (52). Gavage adminis-
tration ofethyl acrylate at a dose of 100 or
200 mg/kg 5 times a week for 24 weeks
induced forestomach papillomas in Tg
mice but not in corresponding non-Tg
mice 26 weeks after the start ofadministra-
tion (7). Forestomach squamous cell carci-
nomas were also observed in 200 mg/kg
ethyl acrylate-treated male Tg mice but not
in corresponding non-Tg mice (7). When
the numbers ofmice having forestomach
squamous cell tumors (papilloma and squa-
mous cell carcinoma) were combined, the
incidence of forestomach squamous cell
tumors in 200 mg/kg ethyl acrylate-treated
male Tg mice was significantly higher than
that in corresponding non-Tg mice or
vehicle-treated control mice (7) The inci-
dence offorestomach papilloma was dose
dependent in the Tg mice.
Ethylene thiourea is known to produce
thyroid neoplasms both in rats and mice
(53). Only female mice were used for
carcinogenicity tests. Mice were fed diets
containing 0.1 or 0.3% of ethylene
thiourea for 28 weeks. Ethylene thiourea at
the dose of 0.1% did not lead to develop-
ment ofeither thyroid tumors or hyperpla-
sia in Tg and non-Tg mice (6), whereas
0.3% ethylene thiourea induced thyroid
adenomas in 26 and 20% ofTg and non-
Tg mice, respectively. Ethylene thiourea at
a dose of 0.3% also induced thyroid
follicular cell hyperplasia in 64 and 76%
(statistically significant vs corresponding
vehicle-treated groups) ofTg and non-Tg
mice, respectively. Results indicate that the
carcinogenic effect ofethylene thiourea is
dose related. Incidence ofthyroid adeno-
carcinoma was also similar, i.e., 9% in Tg
and 4% in non-Tg mice, and no significant
differences were observed between the Tg
and non-Tg mice (6).
Mouse-only single-species carcinogens,
especially nonmutagenic carcinogens that
induce liver tumors, may not be relevant to
carcinogenic risk to humans (55). To
investigate whether rasH2 mice respond to
mouse-only carcinogens, rapid carcino-
genicity testing oftwo Salmonella mutage-
nesis assay-positive carcinogens, i.e.,
6-nitrobenzimidazole (56) and 5-nitro-o-
toluidine (57), and one Salmonella muta-
genesis assay-negative carcinogen, i.e.,
1,1,2-trichloroethane (58), has been con-
ducted (Table 2). Histopathologic exami-
nation ofthe 1,1,2-trichloroethane study
was completed recently.
1,1,2-Trichloroethane induces hepato-
cellular carcinoma and adrenal pheochro-
mocytoma in mice but not in rats (58). In
the NTP 2-year bioassay B6C3F, mice
were treated with 1,1,2-trichloroethane by
gavage at a dose of 195 or 390 mg/kg 5
times a week for 78 weeks (58). Since
substantial numbers of 400 mg 1,1,2-
trichloroethane-treated Tg mice died
within 1 week after the start ofadministra-
tion, the dose of the carcinogen was
reduced. 1,1,2-Trichloroethane was admin-
istered by gavage at a dose of 100 or 200
mg/kg 5 times a week for 24 weeks, and
mice were sacrificed 26 weeks after the start
of administration. Although 200 mg of
1,1,2-trichloroethane induced calcified foci
in the liver ofboth Tg and non-Tg mice, it
induced neither liver tumors nor any other
tumor-types in Tg and non-Tg mice
(Urano et al., unpublished data).
High sensitivity to various carcinogens
is essential in any animal model used for
rapid carcinogenicity testing, but it is also
important to clarify whether the rasH2
mice respond negatively to noncarcinogens.
p-Anisidine (59), 2-chloromethylpyridine
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hydrochloride (60), 8-hydroxyquinoline
(61), and 4-nitro-o-phenylenediamine (62)
are classified as Salmonella mutagenesis
assay-positive noncarcinogens (Table 2).
Resorcinol (63), rotenone (64), xylenes
(mixed) (65), and tetraethylthiuram disul-
fide (66) are classified as Salmonella muta-
genesis assay-negative noncarcinogens
(Table 2).
p-Anisidine was mixed in the feed at a
concentration of 0.225 or 0.45% and
administered for 26 weeks. p-Anisidine
did not induce tumors in either Tg or
non-Tg mice.
8-Hydroxyquinoline, an antimicrobial
agent, is reported to be mutagenic but not
carcinogenic in rodents (61). It was mixed
in the feed at a concentration of 1500 or
3000 ppm and administered for 24 weeks,
and mice were sacrificed 26 weeks after the
start of administration. No significant
tumor induction was observed in either Tg
or non-Tg mice (7).
4-Nitro-o-phenylenediamine, a compo-
nent ofhair dyes, is a mutagenic noncar-
cinogen (62). 4-Nitro-o-phenylenediamine
was mixed in the feed at a concentration of
3750 or 7500 ppm and administered for 24
weeks; mice were sacrificed 26 weeks after
the start ofadministration. Lung adenomas
were induced in 3 of 15 mice in 7500 ppm
4-nitro-o-phenylenediamine-treated male
Tg mice. The incidence oflung adenoma
was slightly higher than the tumor inci-
dences observed in other noncarcinogen-
treated Tg mice; however, the incidence
of lung adenoma was not statistically
significant (7).
Resorcinol, a nonmutagenic non-
carcinogen (63), was administered by gav-
age at a dose of225 mg/kg 5 times a week
for 26 weeks. It did not induce tumors in
either Tg or in non-Tg mice.
Rotenone is used as a pesticide and was
a nonmutagenic noncarcinogen in a 2-year
rodent bioassay (64). Rotenone was mixed
in the feed at a concentration of 600 or
1200 ppm and administered for 24 weeks,
and mice were sacrificed 26 weeks after the
start ofrotenone administration. No tumor
induction was observed in either Tg or
non-Tg mice (7).
Xylenes (mixed) are a nonmutagenic
noncarcinogen tested in a 2-year rodent
bioassay (65). Xylenes (mixed) were
administered by gavage at a dose of500 or
1000 mg/kg 5 times per week for 24
weeks; mice were sacrificed 26 weeks after
the start ofxylene (mixed) administration.
Tumor induction was not observed in
either Tg or non-Tg mice (7).
Carcinogenicity tests of 2-chloro-
methylpyridine and tetraethylthiuram
disulfide are currently under way (Table 2).
Spleen hemangiosarcomas and lung
adenomas are occasionally observed as
spontaneous tumors in the Tg mice.
Forestomach papillomas and skin papillo-
mas are rarely observed, however, so the
incidences ofthese spontaneous tumors are
relatively low (5-8).
AssayValidation
Test results obtained to date are summarized
in Tables 3 and 4. Table 3 lists the names
of the tested chemicals, dose, route of
administration, and presence of rapid
tumor response in Tg mice. Rapid tumor
response means that tumors actually
develop within 26 weeks (28 weeks for eth-
ylene thiourea) in rasH2 mice in response
to tested chemicals. Positive tumor response
(+* in Table 3) means that the incidence of
at least one type oftumor that developed
in chemical-treated Tg mice is significantly
higher (p<0.05, Fisher's exact test) than
that in control vehicle-treated Tg mice.
Negative tumor response (- in Table 3)
means that the incidence of any type of
tumor developed in chemical-treated Tg
mice is < 13% (<2 of 15), or that tumor
incidence is similar for chemical-treated
and vehicle-treated groups. Certain types
ofspontaneous tumors are observed from
time to time at a rate of 1 in 10, and very
rarely at a rate of2 in 10 in Tg mice; there-
fore tumor incidence of< 13% was defined
as negative. Ifthe numbers ofanimals used
are 15 for each chemical-treated group and
10 for each vehicle-treated group, tumor
incidence of.47% (.7 of 15) is required
for statistical significance (i.e., positive
tumor response) even when the tumor inci-
dence ofvehicle-treated controls is 0%.
Therefore, responses classified as neither
positive nor negative were divided into the
following two categories: one that is desig-
nated as (+) in Table 3, i.e., the incidence
of at least one type of tumor that devel-
oped in chemical-treated Tg mice, is
2 25% (.4 of 15) but not statistically sig-
nificant compared to the control group. It
seems possible that chemicals classified in
this category may have the potential to be
carcinogenic. The other category, which is
designated (±) in Table 3, i.e., the inci-
dence of at least one type of tumor that
developed in chemical-treated Tg mice, is
more than 13% but less than 25% (3 of
15). Chemicals in this category may not
have carcinogenic potential. Table 3 also
compares tumor incidence between Tg and
non-Tg mice as well as comparing the
incidence of malignant tumors in the Tg
and non-Tg mice. Table 4 compares tumor
spectra observed in Tg mice treated with
tested chemicals and tumor spectra
observed in 2-year mouse bioassays or in
the literature-cited studies (based on mouse
data) for the same chemicals.
As summarized in Tables 3 and 4, most
ofthe tested mutagenic (trans-species) car-
cinogens induced at least one type oftumor
in carcinogen-treated Tg mice within 26
weeks with a significantly higher incidence
than that in control vehicle-treated Tg
mice. Dose-dependent tumor induction
was observed with most of the chemicals
tested. The results obtained to date clearly
demonstrate that in most cases Tg mice are
much more susceptible to various muta-
genic carcinogens than non-Tg mice.
Tumors develop much sooner in Tg mice
than in non-Tg mice (Table 3). Moreover,
most ofthe malignant tumors are observed
in the carcinogen-treated Tg mice and only
a few or none in the corresponding non-Tg
mice. All of these results indicate that
rasH2 mice are useful for detecting muta-
genic (trans-species) carcinogens.
Integration ofinformation from chemi-
cal structure, mutagenicity, and toxicity
studies may, to a certain extent, be useful
in predicting the carcinogenic potential of
relatively potent genotoxic carcinogens
(67). Detectability of relatively weak car-
cinogens including nonmutagenic (trans-
species) carcinogens is important in
validating the usefulness of rasH2 mice in
carcinogen testing procedures. Whether
the Tg mouse can be used to detect non-
mutagenic carcinogens is especially impor-
tant for pharmaceutical companies because
ifthey are developing products found to be
genotoxic, development may be aban-
doned. Although all studies on nonmuta-
genic carcinogens are not yet completed,
results obtained to date indicate that
nonmutagenic carcinogens may also be
detectable with a high probability by rasH2
mice (Table 3). Dose-dependent tumor
induction was observed with three offive
chemicals tested. It has been demonstrated
that nonmutagenic carcinogens having sin-
gle-site carcinogenic effects, for example,
ethyl acrylate, cannot be detected in p53-
knockout (+/-) and TG.AC models (1).
Although at present it is not known
whether ethyl acrylate is carcinogenic in
humans, our results suggest that rasH2
mice can be used to detect such carcino-
gens (7). Further validation studies are
required, however, before reaching a final
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Table 3. Results of rapid carcinogenicity testing using rasH2 mice.
Route of Rapid tumor Malignanttumors
Chemicals tested Dose administration responsea inTg mice Tumor incidenceb Tg Non-Tg
Mutagenic (Salmonella) carcinogens
p-Cresidine 0.25 or0.5% for 26 wk Feed +* Tg Non-Tg + +
Cyclophosphamidec 30 mg/kg x 2/wk for 25 wk Gavage + Tg Non-Tg +
DENc 90 mg/kg x 1 Intraperitoneal +* Tg>Non-Tg* +
1,2-Dimethylhydrazine9 20mg/kg x 1/wk for 20 wk Subcutaneous +* Tg>Non-Tg* +
4HAQO0e 10 or 20 mg/kg x 1 Intravenous +* Tg>Non-Tg* ++ +
MAMc 20 mg/kg x 1/wk for 6 wk Subcutaneous + Tg>Non-Tg + -
Melphalan 0.3 or 1.5 mg/kg x 1/wk for 26 wk Intraperitoneal + Tg>Non-Tg + -
MNNGC 2.5 mg x 1 Gavage +* Tg>Non-Tg* + -
MNUc 75 mg/kg x 1 or 15 mg/kg x 5 Intraperitoneal +* Tg>Non-Tg* + -
NNKe 3 or 6 mg x 1/wkfor 2 wk Intraperitoneal +* Tg<Non-Tg* + -
4NQOC 15 mg/kg x 1 Subcutaneous +* Tg>Non-Tg* + -
Phenacetine 0.7 or 1.4% for 24wk Feed +* Tg>Non-Tg* + -
Procarbazinee 6 or 12 mg/kg x 3/wk for 24 wk Intraperitoneal + Tg>Non-Tg + -
4,4'-Thiodianilinee 2000 or 4000 ppm for 24 wk Feed +* Tg>Non-Tg* + -
Thiotepae 1 or 2 mg/kg x 3/wk for 24 wk Intraperitoneal + Tg>Non-Tg* + -
Vinyl carbamatef 60 mg/kg x 1 Intraperitoneal +* Tg>Non-Tg* ++ +
4-Vinyl-1-cyclohexene diepoxidee 5 or 10 mg x 5/wkfor 24 wk Dermal +* Tg>Non-Tg* ++ +
Nonmutagenic (Salmonella) carcinogens
Benzenee 50 or 100 mg/kg x 5/wk for 24 wk Gavage +* Tg>Non-Tg* + -
Cyclosporine 10 or 25 mg/kg x 5/wk for 24wk Gavage + Tg>Non-Tg + -
1,4-Dioxanee 0.5 or 1% for 24wk Water + Tg>Non-Tg* + -
Ethyl acrylatee 100 or 200 mg/kg x 5/wk for 24 wk Gavage +* Tg>Non-Tg* + -
Ethylene thiouread 0.3% for 28 wk Feed +* Tg_Non-Tg + +
1,1,2-Trichloroethane 100 or 200 mg/kg Gavage
Mutagenic (Salmonella) noncarcinogens
p-Anisidine 0.225 or 0.45% for 26 wk Feed
8-Hydroxyquinolinee 1500 or 3000 ppm for 24wk Feed
4-Nitro-o-phenylenediaminee 3750 or 7500 ppm for 24 wk Feed + Tg _Non-Tg
Nonmutagenic (Salmonella) noncarcinogens
Resorcinol 225 mg/kg x 5/wkfor26 wk Gavage
Rotenonee 600 or 1200 ppm for 24 wk Feed
Xylene (mixed)e 500 or 1000 mg/kg x 5/wk for 24wk Gavage
fRapid tumor response means that tumors actually developed within 26 weeks (28 weeks for ethylen thiourea) in rasH2 (Tg) mice in response to tested chemicals. (+')
"Positive" indicates that the incidence of at least one type of tumor developed in chemical-treated Tg mice was significantly (p<0.05; Fischer's exacttest) higher than that in
control vehicle-treated Tg mice. (+) indicates that the incidence of at least one type of tumor developed in chemical-treated Tg mice was .25% but not statistically signifi-
cant versus control. )±) "Positive-negative" indicates thatthe incidence of at least one type oftumordeveloped in chemical-treated Tg mice was more than 13% but less than
25%. H-) "Negative" indicates that the incidence of any type of tumor developed in chemical-treated Tg mice <13% or that tumor incidence was similar between the vehicle-
treated control and dosed groups. bTumor incidence: Incidence of at least one type of tumor (in cases of p-cresidine and ethylene thiourea, incidences of diffuse hyperplasia
of urinary bladder and thyroid follicular cell hyperplasia, respectively) developed in chemical-treated Tg mice was statistically different from that of corresponding non-Tg
mice (p<0.05; Fisher's exact test). cData from Yamamoto et al. (5). dData from Yamamoto et al. (6). "Data from Urano et al. (7). fData from Mitsumori et al. (8). 9Data from
Itoh et al. (unpublished data).
conclusion on the usefulness of rasH2 mice
fordetecting nonmutagenic carcinogens.
Nonmutagenic mouse-only carcinogens
may not be relevant to the problem ofcar-
cinogenic risk to humans (55). It has been
suggested that liver damage caused by a
nonmutagenic mouse-only carcinogens,
such as 1,1,2-trichloroethane, is related to
carcinogenic activity of this type of agent
(55). Although 1,1,2-trichloroethane caused
hepatotoxicity in both Tg and non-Tg mice,
it did not induce hepatocellular carcinomas
in either Tg or non-Tg mice. 1,1,2-
Trichloroethane did not induce any other
types of tumors in Tg and non-Tg mice
within 26 weeks, suggesting that rasH2
mice may not respond to nonmutagenic
mouse-only carcinogens. Ifthat is true, the
potential usefulness of this Tg mouse
further increases. Additional validation
studies are required toclarifythis point.
As shown in Table 4, most of the car-
cinogens tested induced some ofthe target
organ tumors in the 2-year bioassay or in
the literature-cited studies as well as certain
types of tumors specific to Tg mice, e.g.,
lung alveolar epithelial tumors, spleen
hemangiosarcomas, forestomach squamous
cell tumors and skin squamous cell tumors.
Because these tumors develop sponta-
neously in aged rasH2 mice, it seems likely
that carcinogens enhance spontaneous
tumorigenesis by providing a certain step
for carcinogenesis. Moreover, because there
are strain differences in target organs and
tumor spectra in carcinogen-induced
tumors (68,69), it is not necessarily true
that rasH2 mice (genetic background:
CB6F1) induce so-called target organ
tumors as observed in B6C3F1 mice (used
for the 2-year mouse bioassay). Therefore,
chemicals that induce tumors in the lung,
forestomach, spleen, and skin in rasH2
mice should be considered carcinogens.
It has been suggested that rasH2 mice
have a low susceptibility to hepatocarcino-
genesis, probably because of their genetic
background (5-8). C57BL/6 mice have
low susceptibility to chemically induced
hepatocarcinogenesis (70,71), whereas
C3H mice are highly susceptible to hepato-
carcinogenesis (69,70). BALB/c mice are
very resistant to hepatocarcinogenesis (69),
and the F1 hybrid offemale C57BL/6 and
male BALB/c has low sensitivity to hepato-
carcinogenesis (44,71). Therefore, it seems
highly possible that CB6F1 mice, the F1
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hybrid of male C57BL/6 and female
BALB/c, are not susceptible to chemically
induced hepatocarcinogenesis. Although
the liver carcinogen 4,4'-thiodianiline
induces hepatocellular carcinomas and
altered foci in the liver (7), incidences of
these lesions in the liver are low (7),
reflecting the low susceptibility ofthis Tg
mouse to liver carcinogens. Alternatively,
liver tumors need more time (>6 months)
to develop even in Tg mice because spon-
taneous liver tumors develop in male Tg
mice with a high incidence until they were
82 weeks ofage (Table 1).
Incidences ofthyroid tumors in ethylene
thiourea- and 4,4'-thiodianiline-treated Tg
mice were similar to those ofcorrespond-
ing carcinogen-treated non-Tg mice (Table
3) (7). It is well known that thyroid car-
cinogenesis in rodents is a typical example
ofhormonal carcinogenesis (55). Serum
levels ofthyroxine and triiodothyronine are
actually decreased and thyroid-stimulating
hormone is increased after rodents are
treated with ethylene thiourea (53).
Hypersecretion ofthyroid-stimulating hor-
mone may promote hyperplasia and even-
tually thyroid adenomas and carcinomas
(55). Similar incidences ofthyroid tumors
in treated Tg and corresponding non-Tg
mice suggest that hormonal carcinogenesis
may not be enhanced in rasH2 mice.
Additional studies are required to clarify
whether this peculiar outcome is thyroid
specific. The study on diethylstilbestrol is
currently underway.
Because false-positive errors in human
carcinogen identification may hinder appro-
priate drug development, overprediction of
carcinogenic potential should be avoided as
much as possible. Therefore, it must be
determined whether rasH2 mice respond
negatively to noncarcinogens. The results
obtained to date clearly show that rasH2
mice do not respond to nonmutagenic non-
carcinogens. As for mutagenic noncarcino-
gens, one ofthreemutagenic noncarcinogens
(e.g., 4-nitro-o-phenylene diamine) induced
lung tumors in Tg mice with slightly higher
incidence than other noncarcinogens (7).
Although incidences ofspontaneous tumors
are generally low in this testing system, lung
tumors are most frequently observed as
spontaneous tumors (5-8). Therefore, a
slight increase in lung tumor incidence may
not have carcinogenic significance. On the
other hand, however, a slight increase in
incidences ofspontaneous tumors may hin-
der assessment ofthe carcinogenic potential
ofborderline chemicals. Increasing the num-
ber ofanimals used in each test group may
remedy this problem (this point is further
discussed in the next paragraph). In any
event, further validation studies are required
to confirm the absence offalse positive
response of rasH2 mice to noncarcinogens,
especiallymutagenic noncarcinogens.
In the conventional 2-year bioassay,
incidences ofspontaneous tumors are high;
thus the discrimination between chemically
induced and spontaneously generated
tumors may occasionally become difficult.
Incidences ofspontaneous tumors in rasH2
mice are low, at least within the time frame
ofcarcinogenicity testing terminated at 33
to 35 weeks ofage (5-8). Thus, in general,
spontaneous tumors do not practically hin-
der assessment ofthe carcinogenic potential
oftested chemicals. However, several muta-
genic carcinogens, e.g., MAM, melphalan,
procarbazine, and several nonmutagenic
carcinogens, such as cyclosporin and 1,4-
dioxane, did not show statistically signifi-
cant differences from controls even though
the tumor incidence was greater than or
equal to 25% (.4 of 15) in treated animals
(Table 3). The main reason this problem
arises is due to the insufficient number of
animals used for the testing, especially for
the vehicle-treated control groups (10 ani-
mals each). When this project was begun,
numbers ofanimals available for each test-
ingwere limited. Thus, the numberofvehi-
cle-treated animals should have been
reduced. Reducing the numbers ofanimals
resulted in a difficult situation with statisti-
cal analyses of the borderline data. The
incidence of such equivocal outcomes
might possibly be reduced by increasing
numbers ofanimals used (at least 15 to 20
animals are necessary for each group). Ifan
equivocal result is obtained with a novel
compound even when using a sufficient
number ofanimals and appropriate doses,
prolongation ofthe observation period to
more than 6 months might provide more
definitive results. A 2-year rat bioassay
should be conducted in such cases. Further
validation studies (such as the ILSI/HESI
project in which 15 animals are used for
each group) are required to clarify this
point. Again the relatively low incidence of
spontaneous tumors and the high sensitivity
to carcinogens allow us to reduce the num-
ber ofanimals (compared with those in the
2-year bioassay) for testing. Reduction in
the number ofanimals used and in dura-
tion ofthe experimental period (compared
with those in the 2-year bioassay) markedly
decrease overall costs oftesting. The valida-
tion studies described here revealed that the
rasH2 mouse appears to be promising as an
animal model for a rapid carcinogenicity
testingsystem.
To scientifically justify the usefulness of
this rapid carcinogenicity testing system, it
appears important to clarify the mechanism
ofrapid tumor induction in rasH2 mice on
molecular bases. Lung alveolar epithelial
tumors (adenomas/adenocarcinomas) were
frequently induced in rasH2 mice after
administration of various carcinogens.
Incidences oftransgene mutations (point
mutation at codon 61) in vinyl carbamate-
induced lung tumors were very low, i.e.,
approximately 7% (8). Lung tumors
induced by other carcinogens also had a
relatively low incidence oftransgene muta-
tions, i.e., 6 % on average (0-24% depend-
ing on carcinogens tested) (S Wakana et al.,
unpublished data). The Ki-ras gene has
been proposed as a determinant oflung
tumor susceptibility in mouse strains, and
point mutations ofthe Ki-rasgene are actu-
ally detected with high frequency in lung
tumors (72-74). Consistent with previous
findings, point mutations ofthe murine Ki-
ras gene either on codon 12 or 61 were
observed in 70% of vinyl carbamate-
induced lung tumors in non-Tg mice (8).
However, Ki-ras mutations were never
observed in lung tumors developed in vinyl
carbamate-treated Tg mice (8). Moreover,
Ki-ras mutations were never observed in
lung tumors induced by either phenacetin,
procarbazine, DEN, NNK, or benzene in
rasH2 mice (S Wakana et al., unpublished
data). These results show that point muta-
tions ofthe transgene and the murine Ki-
ras gene do not play a major role in lung
tumor induction by various carcinogens in
rasH2 mice, indicating that the mechanism
oflung tumor induction in this Tg mouse
is different from that in non-Tg littermates.
Our preliminary results suggest that the
enhanced lung tumor induction in Tg mice
is related neither to overexpression oftrans-
gene nor to microsatellite instability (S
Wakana et al., unpublished data). Further
studies on molecular analyses such as detec-
tion ofloss ofheterozygosity are now under
way to clarify the mechanism of rapid
tumor induction in this Tg mouse.
Perspectives
The interlaboratory validation studies
between the United States and Japan are
continuing. RR Maronpot at the National
Institute ofEnvironmental Health Sciences
(NIEHS) is in charge ofthe U.S. studies.
Table 5 lists six chemicals-vinyl carba-
mate, p-cresidine, cyclosporin, resorcinol,
melphalan, and p-anisidine-that have
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been subjected to the interlaboratory
validation studies. CIEA has supplied Tg
mice to NIEHS. All chemicals have been
tested under similar experimental proto-
cols. Although the validation studies are
not complete, similar results have been
obtained in the United States andJapan.
An intensive survey of databases of
rodent carcinogenicity studies conducted
over the past 25 years revealed that the rat
is more sensitive in detecting carcinogens
than the mouse; and mouse-only tumors,
especially liver tumors, have almost no rele-
vance to carcinogenic risk in humans (55).
Current regulatory requirements for the
assessment ofthe carcinogenic potential of
chemicals in the European Union (EU),
United States, and Japan stipulate long-
term rodent carcinogenicity studies in two
rodent species. Because ofthe cost oflong-
term bioassays, their extensive use oflarge
numbers ofanimals, their poor mechanistic
basis, and their relatively low relevance to
human risk assessment, the International
Conference on Harmonization ofTechnical
Requirements for the Registration of
Pharmaceuticals for Human Use (ICH) is
considering whether the use of2-year car-
cinogenicity tests with two rodent species
could be reduced without compromising
human safety. Recent ICH-Expert Working
Group draft guidelines proposed that the
carcinogenic potential ofpharmaceuticals
Table 5. Interlaboratory validation studies between the United States and Japan on rapid carcinogenicity testing
using rasH2 mice.
Institutea Status
Chemicals Japan United States Japan United States
Vinyl carbamate NIHS NIEHS Completed Completed
p-Cresidine NIHS NIEHS Completed Completed
Cyclosporin CIEA NIEHS Completed Underway
Resorcinol Industry-i b NIEHS Completed Completed
Melphalan Industry-2c NIEHS Completed Completed
p-Anisidine NIHS NIEHS Completed Completed
&Sites where carcinogenicity tests were conducted or are being conducted. hYamanouchi Pharmaceutical Co. Ltd.
cKyowa Hakko Kogyo Co.
could be evaluated from the data of one
long-term conventional rodent (rat) car-
cinogenicity study plus data from one
short- or medium-term testing system such
as transgenic models, newborn models, or
initiation/promotion models.
Studies on validation of the use of
p53-knockout mice and/or TG.AC mice
(v-Ha-ras transgenic mice) as short-term
bioassay models for carcinogen identifi-
cation have been conducted by R
Tennant and his colleagues at NIEHS
(1,2). At present, amongvarious genetically
engineered animals, rasH2 mice, p53-
knockout mice, TG.AC mice, and XPA-
deficient mice are the most promising as
short-term bioassay models for identifying
chemical carcinogens.
ILSI/HESI in Washington, DC,
under the direction of D Robinson and J
MacDonald, has recently organized study
groups comprising governmental insti-
tutes, private research institutes, and
more than 30 pharmaceutical companies
from the EU, United States, andJapan to
validate genetically engineered mice, e.g.,
rasH2 mice, p53-knockout (+/-) mice,
TG.AC mice, and XPA-deficient (-/-)
mice, as animal models for short-term
carcinogenicity testing. More than 20
chemicals will be tested in each model in
the project.
Although the usefulness and the limita-
tions of the rapid carcinogenicity testing
system using rasH2 mice have not yet been
fully determined, a considerable amount of
data that demonstrate potential usefulness
have already been accumulated as described
in this review.
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